Connecticut
An Assessment of a Restrictive Certificate of Need Regime
Regulatory Scope
What CON Covers in Connecticut
Covered Services & Facilities
Connecticut's CON law is comprehensive, covering a wide array of healthcare services and facilities. Any significant capital expenditure, service addition, or equipment acquisition requires state approval.
- New Hospitals & Long-Term Care Facilities
- Hospital Expansions, Sales, or Transfers
- Freestanding Emergency Departments
- Ambulatory Surgery Centers (ASCs)
- Cardiac Catheterization & Surgery Programs
- CT, MRI, PET Scanners & Linear Accelerators
- Increases in Licensed Beds or Operating Rooms
- Termination of Inpatient or Outpatient Services
Application Process
The process is managed by the Office of Health Strategy (OHS) for most facilities and the Department of Social Services (DSS) for long-term care. It involves fees, lengthy reviews, and public hearings where competitors can intervene.
| Entity | Fee | Timeline |
|---|---|---|
| OHS (Hospitals) | $1k - $10k | ~183-434 days (median) |
| DSS (Nursing Homes) | Statutory | ~6 months (target) |
Market Impact
Who Benefits from CON?
Dominant Health Systems
Connecticut's hospital market is a duopoly. Two behemoth systems, Yale New Haven Health and Hartford HealthCare, control approximately 60% of the state's hospital revenue, creating a highly concentrated and anti-competitive landscape.
Insurer Landscape
The insurance market is similarly concentrated, with Anthem (BCBS) and UnitedHealthcare holding the lion's share of the commercial market, further limiting consumer choice.
Case Law
The Human Cost of CON
Norwalk Hospital vs. The State (2014)
In a clear example of CON laws restricting access to care, Norwalk Hospital was denied a certificate to offer elective angioplasty (PCI) services. The state's rationale was the hospital's lack of an on-site cardiac surgery backup—a requirement that protects incumbent hospitals with full-service cardiac programs. This decision forced patients in the Norwalk area to travel farther for a common, life-saving procedure, prioritizing market stability over patient convenience and access.
Reform
Legislative Status
No Meaningful Reform
Despite minor tweaks to fees and timelines in recent years (2022-2025), Connecticut's core CON law remains firmly in place. The legislature has shown no appetite for a full repeal. Instead, recent changes have focused on administrative adjustments, such as creating a graduated fee schedule and an emergency CON process for bankrupt hospitals. These actions do not address the fundamental anti-competitive nature of the law, which continues to shield established players from competition at the expense of innovation and patient choice.
The Rojas Report Take
Connecticut’s Certificate of Need program is a textbook case of regulatory capture, a relic that serves not the public, but the entrenched duopoly of Yale New Haven Health and Hartford HealthCare. With a CON score of 90 out of 100, the state operates one of the most restrictive regimes in the nation, effectively granting a government-sanctioned franchise to these two giants, who collectively command over 60% of the market.
The data is damning. The state’s own records show review times stretching from 183 to over 434 days, a bureaucratic moat that deters all but the most capitalized incumbents. The 2014 denial of Norwalk Hospital’s angioplasty program is not an anomaly; it is the system working as intended—to protect established revenue streams. While legislators tinker with fee schedules, they ignore the elephant in the room: a law that inflates costs, limits access, and stifles the very competition that could discipline a consolidated market.
Connecticut’s CON law is not a tool for ensuring quality; it is a barrier to entry that perpetuates a healthcare cartel. It’s time to dismantle it.
Go Deeper
Related Content
The CON Problem
An overview of how Certificate of Need laws create government-enforced monopolies in healthcare across the United States.
Maryland CON Profile
Certificate of Need investigation for Maryland.
The 340B Drug Program
$81.4B in discounted drugs. Zero disclosure requirements.